Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Revenue (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Revenue for 13 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 33.3% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.6 million through Dec 2025, up 34.47% year-over-year, with the annual reading at $107.5 million for FY2025, 66.92% up from the prior year.
  • Revenue for Q4 2025 was $25.0 million at Theravance Biopharma, up from $20.0 million in the prior quarter.
  • The five-year high for Revenue was $26.2 million in Q2 2025, with the low at $2.5 million in Q1 2022.
  • Average Revenue over 5 years is $15.2 million, with a median of $14.6 million recorded in 2022.
  • The sharpest move saw Revenue surged 850.47% in 2021, then tumbled 82.46% in 2022.
  • Over 5 years, Revenue stood at $14.9 million in 2021, then fell by 1.99% to $14.6 million in 2022, then rose by 19.91% to $17.6 million in 2023, then grew by 6.77% to $18.8 million in 2024, then surged by 33.3% to $25.0 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $25.0 million, $20.0 million, and $26.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.